Issuers of listed transferable securities are required to provide Oslo Børs with an annual statement of information made available to the public, cf the Norwegian Securities Trading Act section 5-11 first subsection. Attached you will find an annual overview for NorDiag ASA for the period of April 9 2010 to April 7 2011.
 
Contact:       CFO Tone Kvåle, phone + 47 915 19576.
 
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 41.1 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.

For further information - www.nordiag.com

Read the attached overview here

Read the notice in Norwegian here